Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 11, 2005 05:12 ET | Source: Trigen

Trigen Completes Eur 26.5 Million Financing Round

MUNICH, Germany and LONDON, Oct. 11, 2005 (PRIMEZONE) -- Trigen Holdings AG, the cardiovascular drug discovery and development company, today announced the completion of a 26.5m euro (US$31.9m)...
August 09, 2005 19:22 ET | Source: Trigen

Trigen Announces the Successful Completion of a Phase II Study of TGN 255 for Anticoagulation in Haemodialysis

MUNICH and LONDON, Aug. 9, 2005 (PRIMEZONE) -- Trigen Holdings AG today announced the preliminary results of its Phase II study of anticoagulation in haemodialysis for its novel intravenous...
April 11, 2005 02:09 ET | Source: Trigen

Trigen and ProCorde Merge to Create Europe's First Broad-based Cardiovascular Biotech Company

-- Complete pipeline of novel, competitive, clinical-stage products addressing major in-hospital and out-patient thrombosis markets -- Extensive portfolio of pre-clinical and discovery-stage ...
November 23, 2004 02:08 ET | Source: Trigen

Trigen and Eurand announce a development collaboration for Trigen's novel oral anticoagulant, TGN 167

LONDON and MILAN, Nov. 23, 2004 (PRIMEZONE) -- Trigen Ltd and Eurand today announced a collaboration to develop controlled-release formulations of Trigen's highly-selective, novel oral anticoagulant,...
December 16, 2003 02:16 ET | Source: Trigen

Trigen's Novel Oral Anti-Coagulant, TGN 167, Successfully Completes Phase I Study

LONDON, Dec. 16, 2003 (PRIMEZONE) -- Trigen Ltd today announced the successful completion of a Phase I dose escalation study for its highly selective oral direct thrombin inhibitor (DTI), TGN 167,...
December 09, 2003 02:08 ET | Source: Trigen

Trigen Presents Data on a Neutralising Agent for its Anti-Coagulant Direct Thrombin Inhibitors

LONDON, Dec. 09, 2003 (PRIMEZONE) -- Trigen Ltd today announced that preclinical studies with a neutralising agent showed a specific, rapid and complete reversal of the anti-coagulant properties of...
December 03, 2003 02:09 ET | Source: Trigen

Trigen's i.v. Anticoagulant, TGN 255, Successfully Completes Phase I PK/PD Study

LONDON, U.K., Dec. 03, 2003 (PRIMEZONE) -- Trigen Ltd today announced the successful completion of a Phase I dose escalation study for its intravenous direct thrombin inhibitor, TGN 255, which is...
November 18, 2003 02:18 ET | Source: Trigen

Trigen Advances Next Generation Anti-Coagulant, Direct Thrombin Inhibitors

LONDON, Nov. 18, 2003 (PRIMEZONE) -- Trigen Ltd today announced that it has successfully identified two novel, competitive clinical candidates from its Direct Thrombin Inhibitor (DTI) programme,...
August 01, 2002 04:25 ET | Source: Trigen

Trigen Completes Management Team

LONDON, August 1, 2002 (PRIMEZONE) -- Trigen Ltd. today announced the appointment of Dr. Suresh Chahwala as VP Drug Discovery and Dr. Sophie Combe as VP Clinical Development. Both appointments bring...
May 09, 2002 03:15 ET | Source: Trigen

Trigen Expands Executive Management Team

LONDON, May 9, 2002 (PRIMEZONE) -- Trigen Ltd. today announced the appointment of Tony Kennedy as VP Development and Oliver Boucher as VP Commercial Development. "We are delighted that Tony and...